Targeted breast cancer drug extends lives of patients in Phase III trial
Drug Discovery World
DECEMBER 9, 2022
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. . The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. .
Let's personalize your content